|
|
|
|
|
 |
News and Press Releases |
 |
TAGRISSOTM (osimertinib) DEMONSTRATED UNPRECEDENTED DISEASE-FREE SURVIVAL IN THE ADJUVANT TREATMENT OF STAGE IB-IIIA COMPLETELY RESECTED PATIENTS WITH EGFR MUTATION
Detailed results from the Phase III ADAURA trial showed AstraZeneca’s
Tagrisso (osimertinib) demonstrated a statistically significant and
clinically meaningful improvement in disease-free survival (DFS) in the
adjuvant treatment of patients with early-stage (IB, II and IIIA)
epidermal growth factor receptor-mutated (EGFRm) non-small cell lung
cancer (NSCLC) after complete tumour resection with curative intent.
More info >> |
|
 |
White Papers |
 |
|
Device Develop for Combo Products
Phillips-Medisize
Combination products are defined as therapeutics combining two or more products (drug/device, biologics/device, biologics/drugs or drug/device/biologics), regulated and sold as a single unit. As these pharmaceutical and biological therapies and treatments have evolved, so has the need to develop appropriate delivery mechanisms for these applications. When developing a combination product, there are many things that need to be considered – the critical relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding ‘user’ needs, determining product requirements, as well as, device manufacturing variation.
More info >> |
|
 |
Industry Events |
 |
World Vaccine Congress Europe
18-21 October 2020, Barcelona, Spain
The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >> |
|
|
